RODAKS HEMATOLOGY
問題一覧
1
d. Four gamma chains
2
d. Metamyelocyte
3
b. Eosinophils and basophils
4
a. Degrading antigen and presenting it to lymphocytes
5
d. Plasma cell
6
a. Pelger-Huët anomaly
7
d.. May-Hegglin anomaly
8
c. Alder-Reilly anomaly
9
b. Gaucher disease
10
d. All of the above
11
c. IL-2 receptor
12
c. Döhle bodies
13
a. Solid tumors
14
b. HTLV-1
15
d. Allowing cells with damaged DNA to progress through the cell cycle
16
Which one of the following is an example of a tumor sup- pressor gene? a. ABL1 b. RARA c. TP53 d. JAK2
17
d. Targeted therapy
18
b. 20%
19
b. Lipids
20
b. Monocytic
21
d. t(15;17)(q22;q12)
22
b. AML with t(16;16)(p13;q22)
23
c. AML with t(9;11)(p22;q23)
24
c. Acute monoblastic/monocytic leukemia
25
b. Pronormoblasts and basophilic normoblasts
26
b. Acute megakaryoblastic
27
c. t(9;22)
28
d. FISH positive for BCR-ABL1 fusion
29
c. JAK2 V617F
30
c. Erythrocytosis, thrombocytosis, and granulocytosis
31
a. Teardrop-shaped erythrocytes, nucleated RBCs, immature granulocytes
32
b. ET
33
a. Dyspoiesis
34
a. Popcorn cells
35
b. GP IIb/IIIa
36
a. VWF
37
d. Phosphatidylserine
38
c. Dense tubular system
39
a. Serotonin
40
a. Serotonin
41
d. Prostacyclin
42
c. Are largely composed of platelets and VWF
43
b. Endothelial cell
44
a. Lead to the formation of a stable fibrin clot
45
c. Tissue factor
46
b. Fibrinogen
47
d. Carboxylates the factors to allow calcium binding
48
c. APC and protein S
49
d. Factor XIII
50
b. Mucosal bleeding
51
d. Bleeding into the joints (hemarthroses)
52
a. Glanzmann thrombasthenia
53
b. Abnormal platelet response to ristocetin
54
a. Thromboxane A2
55
b. Factor VII deficiency, the PT
56
c. Hypofibrinogenemia
57
a. Type1
58
b. Subtype 2B
59
b. Vitamin K and four-factor PCC
60
d. Factor XIII
61
a. rFVIIa
62
c. Factor V assay
63
a. APC resistance (factor V Leiden mutation)
64
b. DRVVT
65
b. 2.5
66
c. 16
67
d. Fetal hemoglobin
68
d. 21% to 27%
69
a. 2
70
d. Inflammation
71
d. Increasing the acute angle of the pusher slide
72
c. The buffer was too acidic
73
a. Rouleaux
74
c. 11.8 x 10^9/L
75
c. 200,000
76
b. 44,000
77
b. The platelets are adhering to WBCs.
78
b. Internal complexity of the cell
79
c. MCV will be increased and RBC count will be decreased.
80
c. MCV
81
c. Diagnosis of leukemias and lymphomas
82
b. It is expressed on all hematopoietic cells, with the exception of megakaryocytes and late erythroid precursors
83
a. CD71
84
b. CD19, CD34, and CD10
85
a. It is best defined as selection of a target population for flow cytometric analysis
86
a. Loss of certain antigens compared with the normal T cell population
87
c. CD15, CD33, and CD13
88
c. Clot-based test results are falsely prolonged
89
a. Platelet aggregometry
90
b. 10,000/uL
91
a. 0.32 mL
92
d. Glanzmann thrombasthenia
93
b. Serotonin release assay
94
b. Ristocetin
95
b. Factor VII
96
a. Vitamin K deficiency
97
b. Lupus anticoagulant
98
d. DIC
99
c. Photo-optical clot detection
100
a. It is not affected by lipemia in the test specimen
other names parasitology
other names parasitology
Yves Laure Pimentel · 70問 · 2年前other names parasitology
other names parasitology
70問 • 2年前PARASITOLOGY
PARASITOLOGY
Yves Laure Pimentel · 111問 · 2年前PARASITOLOGY
PARASITOLOGY
111問 • 2年前HTMLBE
HTMLBE
Yves Laure Pimentel · 64問 · 2年前HTMLBE
HTMLBE
64問 • 2年前CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR
CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR
Yves Laure Pimentel · 61問 · 2年前CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR
CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR
61問 • 2年前HISTOPATHOLOGY
HISTOPATHOLOGY
Yves Laure Pimentel · 69問 · 2年前HISTOPATHOLOGY
HISTOPATHOLOGY
69問 • 2年前CC-2 SPECTROPHOTOMETRY
CC-2 SPECTROPHOTOMETRY
Yves Laure Pimentel · 100問 · 2年前CC-2 SPECTROPHOTOMETRY
CC-2 SPECTROPHOTOMETRY
100問 • 2年前CC-3 ELECTROPHORESIS
CC-3 ELECTROPHORESIS
Yves Laure Pimentel · 41問 · 2年前CC-3 ELECTROPHORESIS
CC-3 ELECTROPHORESIS
41問 • 2年前AUBF LAB SAFETY
AUBF LAB SAFETY
Yves Laure Pimentel · 87問 · 2年前AUBF LAB SAFETY
AUBF LAB SAFETY
87問 • 2年前CSF 1
CSF 1
Yves Laure Pimentel · 100問 · 2年前CSF 1
CSF 1
100問 • 2年前CSF 2
CSF 2
Yves Laure Pimentel · 82問 · 2年前CSF 2
CSF 2
82問 • 2年前SEMEN 1
SEMEN 1
Yves Laure Pimentel · 100問 · 2年前SEMEN 1
SEMEN 1
100問 • 2年前SEMEN 2
SEMEN 2
Yves Laure Pimentel · 7問 · 2年前SEMEN 2
SEMEN 2
7問 • 2年前SYNOVIAL FLUID 1
SYNOVIAL FLUID 1
Yves Laure Pimentel · 100問 · 2年前SYNOVIAL FLUID 1
SYNOVIAL FLUID 1
100問 • 2年前SYNOVIAL FLUID 2
SYNOVIAL FLUID 2
Yves Laure Pimentel · 6問 · 2年前SYNOVIAL FLUID 2
SYNOVIAL FLUID 2
6問 • 2年前SEROUS FLUID
SEROUS FLUID
Yves Laure Pimentel · 25問 · 2年前SEROUS FLUID
SEROUS FLUID
25問 • 2年前PLEURAL FLUID
PLEURAL FLUID
Yves Laure Pimentel · 44問 · 2年前PLEURAL FLUID
PLEURAL FLUID
44問 • 2年前PERICARDIAL FLUID
PERICARDIAL FLUID
Yves Laure Pimentel · 18問 · 2年前PERICARDIAL FLUID
PERICARDIAL FLUID
18問 • 2年前PERITONEAL FLUID/ ASCITIC FLUID
PERITONEAL FLUID/ ASCITIC FLUID
Yves Laure Pimentel · 30問 · 2年前PERITONEAL FLUID/ ASCITIC FLUID
PERITONEAL FLUID/ ASCITIC FLUID
30問 • 2年前AMNIOTIC FLUID
AMNIOTIC FLUID
Yves Laure Pimentel · 92問 · 2年前AMNIOTIC FLUID
AMNIOTIC FLUID
92問 • 2年前FECALYSIS
FECALYSIS
Yves Laure Pimentel · 80問 · 2年前FECALYSIS
FECALYSIS
80問 • 2年前OTHER BODY FLUIDS
OTHER BODY FLUIDS
Yves Laure Pimentel · 89問 · 2年前OTHER BODY FLUIDS
OTHER BODY FLUIDS
89問 • 2年前MTLBE- SUHO NOTES
MTLBE- SUHO NOTES
Yves Laure Pimentel · 86問 · 2年前MTLBE- SUHO NOTES
MTLBE- SUHO NOTES
86問 • 2年前MTLBE..
MTLBE..
Yves Laure Pimentel · 35問 · 2年前MTLBE..
MTLBE..
35問 • 2年前CC- CHROMATOGRAPHY
CC- CHROMATOGRAPHY
Yves Laure Pimentel · 19問 · 1年前CC- CHROMATOGRAPHY
CC- CHROMATOGRAPHY
19問 • 1年前CC-OSMOMETRY
CC-OSMOMETRY
Yves Laure Pimentel · 14問 · 1年前CC-OSMOMETRY
CC-OSMOMETRY
14問 • 1年前CC-ELECTROCHEMISTRY TECHNIQUES
CC-ELECTROCHEMISTRY TECHNIQUES
Yves Laure Pimentel · 43問 · 1年前CC-ELECTROCHEMISTRY TECHNIQUES
CC-ELECTROCHEMISTRY TECHNIQUES
43問 • 1年前CC- CARBOHYDRATES
CC- CARBOHYDRATES
Yves Laure Pimentel · 49問 · 2年前CC- CARBOHYDRATES
CC- CARBOHYDRATES
49問 • 2年前CC- DIABETES MELLITUS
CC- DIABETES MELLITUS
Yves Laure Pimentel · 97問 · 2年前CC- DIABETES MELLITUS
CC- DIABETES MELLITUS
97問 • 2年前MAJOR LIPOPROTEINS
MAJOR LIPOPROTEINS
Yves Laure Pimentel · 57問 · 2年前MAJOR LIPOPROTEINS
MAJOR LIPOPROTEINS
57問 • 2年前MINOR LIPOPROTEINS
MINOR LIPOPROTEINS
Yves Laure Pimentel · 63問 · 2年前MINOR LIPOPROTEINS
MINOR LIPOPROTEINS
63問 • 2年前PROTEINS
PROTEINS
Yves Laure Pimentel · 37問 · 2年前PROTEINS
PROTEINS
37問 • 2年前PLASMA PROTEINS 1
PLASMA PROTEINS 1
Yves Laure Pimentel · 91問 · 2年前PLASMA PROTEINS 1
PLASMA PROTEINS 1
91問 • 2年前PLASMA PROTEINS 2 (ALPHA 2 REGION)
PLASMA PROTEINS 2 (ALPHA 2 REGION)
Yves Laure Pimentel · 98問 · 2年前PLASMA PROTEINS 2 (ALPHA 2 REGION)
PLASMA PROTEINS 2 (ALPHA 2 REGION)
98問 • 2年前MISCELLANEOUS PROTEINS
MISCELLANEOUS PROTEINS
Yves Laure Pimentel · 61問 · 2年前MISCELLANEOUS PROTEINS
MISCELLANEOUS PROTEINS
61問 • 2年前Liver Function Test 1
Liver Function Test 1
Yves Laure Pimentel · 100問 · 2年前Liver Function Test 1
Liver Function Test 1
100問 • 2年前Liver Function Test 2
Liver Function Test 2
Yves Laure Pimentel · 96問 · 2年前Liver Function Test 2
Liver Function Test 2
96問 • 2年前TUMOR MARKERS
TUMOR MARKERS
Yves Laure Pimentel · 33問 · 2年前TUMOR MARKERS
TUMOR MARKERS
33問 • 2年前KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE
KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE
Yves Laure Pimentel · 41問 · 2年前KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE
KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE
41問 • 2年前GLYCOGEN STORAGE DISEASES
GLYCOGEN STORAGE DISEASES
Yves Laure Pimentel · 17問 · 2年前GLYCOGEN STORAGE DISEASES
GLYCOGEN STORAGE DISEASES
17問 • 2年前LIPID STORAGE DISEASES
LIPID STORAGE DISEASES
Yves Laure Pimentel · 14問 · 2年前LIPID STORAGE DISEASES
LIPID STORAGE DISEASES
14問 • 2年前PROTEINS
PROTEINS
Yves Laure Pimentel · 71問 · 2年前PROTEINS
PROTEINS
71問 • 2年前QUICK FIRE- ELECTRODES
QUICK FIRE- ELECTRODES
Yves Laure Pimentel · 7問 · 2年前QUICK FIRE- ELECTRODES
QUICK FIRE- ELECTRODES
7問 • 2年前ELECTROLYTES
ELECTROLYTES
Yves Laure Pimentel · 10問 · 2年前ELECTROLYTES
ELECTROLYTES
10問 • 2年前DRUGS
DRUGS
Yves Laure Pimentel · 27問 · 2年前DRUGS
DRUGS
27問 • 2年前TOXIC AGENTS:
TOXIC AGENTS:
Yves Laure Pimentel · 12問 · 2年前TOXIC AGENTS:
TOXIC AGENTS:
12問 • 2年前HEMATOLOGY 1 (HEMATOPOIESIS 1)
HEMATOLOGY 1 (HEMATOPOIESIS 1)
Yves Laure Pimentel · 100問 · 2年前HEMATOLOGY 1 (HEMATOPOIESIS 1)
HEMATOLOGY 1 (HEMATOPOIESIS 1)
100問 • 2年前HEMATOLOGY (HEMATOPOIESIS 2)
HEMATOLOGY (HEMATOPOIESIS 2)
Yves Laure Pimentel · 29問 · 2年前HEMATOLOGY (HEMATOPOIESIS 2)
HEMATOLOGY (HEMATOPOIESIS 2)
29問 • 2年前hema diseases
hema diseases
Yves Laure Pimentel · 25問 · 2年前hema diseases
hema diseases
25問 • 2年前AML
AML
Yves Laure Pimentel · 43問 · 2年前AML
AML
43問 • 2年前GLOBIN SYNTHESIS
GLOBIN SYNTHESIS
Yves Laure Pimentel · 71問 · 2年前GLOBIN SYNTHESIS
GLOBIN SYNTHESIS
71問 • 2年前HEMATOLOGY REFERENCE RANGES
HEMATOLOGY REFERENCE RANGES
Yves Laure Pimentel · 31問 · 2年前HEMATOLOGY REFERENCE RANGES
HEMATOLOGY REFERENCE RANGES
31問 • 2年前DISORDERS OF PRIMARY HEMOSTASIS
DISORDERS OF PRIMARY HEMOSTASIS
Yves Laure Pimentel · 34問 · 2年前DISORDERS OF PRIMARY HEMOSTASIS
DISORDERS OF PRIMARY HEMOSTASIS
34問 • 2年前PLATELET DISORDERS
PLATELET DISORDERS
Yves Laure Pimentel · 37問 · 2年前PLATELET DISORDERS
PLATELET DISORDERS
37問 • 2年前CHARACTERISTICS OF CLOTTING FACTORS
CHARACTERISTICS OF CLOTTING FACTORS
Yves Laure Pimentel · 100問 · 2年前CHARACTERISTICS OF CLOTTING FACTORS
CHARACTERISTICS OF CLOTTING FACTORS
100問 • 2年前4. CLASSIFICATION OF MACROPHAGE
4. CLASSIFICATION OF MACROPHAGE
Yves Laure Pimentel · 12問 · 2年前4. CLASSIFICATION OF MACROPHAGE
4. CLASSIFICATION OF MACROPHAGE
12問 • 2年前3. NATURAL OR INNATE IMMUNITY
3. NATURAL OR INNATE IMMUNITY
Yves Laure Pimentel · 39問 · 2年前3. NATURAL OR INNATE IMMUNITY
3. NATURAL OR INNATE IMMUNITY
39問 • 2年前5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)
5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)
Yves Laure Pimentel · 55問 · 2年前5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)
5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)
55問 • 2年前6. PHAGOCYTOSIS Chemotaxis
6. PHAGOCYTOSIS Chemotaxis
Yves Laure Pimentel · 37問 · 2年前6. PHAGOCYTOSIS Chemotaxis
6. PHAGOCYTOSIS Chemotaxis
37問 • 2年前8. NATURE OF ANTIGEN
8. NATURE OF ANTIGEN
Yves Laure Pimentel · 44問 · 2年前8. NATURE OF ANTIGEN
8. NATURE OF ANTIGEN
44問 • 2年前9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN
9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN
Yves Laure Pimentel · 50問 · 2年前9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN
9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN
50問 • 2年前1. HISTORY
1. HISTORY
Yves Laure Pimentel · 69問 · 2年前1. HISTORY
1. HISTORY
69問 • 2年前2. TYPES OF IMMUNITY
2. TYPES OF IMMUNITY
Yves Laure Pimentel · 38問 · 2年前2. TYPES OF IMMUNITY
2. TYPES OF IMMUNITY
38問 • 2年前7. PHAGOCYTOSIS Engulfment and Digestion
7. PHAGOCYTOSIS Engulfment and Digestion
Yves Laure Pimentel · 21問 · 2年前7. PHAGOCYTOSIS Engulfment and Digestion
7. PHAGOCYTOSIS Engulfment and Digestion
21問 • 2年前8. PHAGOCYTOSIS EXOCYTOSIS
8. PHAGOCYTOSIS EXOCYTOSIS
Yves Laure Pimentel · 15問 · 2年前8. PHAGOCYTOSIS EXOCYTOSIS
8. PHAGOCYTOSIS EXOCYTOSIS
15問 • 2年前10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)
10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)
Yves Laure Pimentel · 32問 · 2年前10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)
10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)
32問 • 2年前11. TRANSPLANTATION IMMUNOLOGY
11. TRANSPLANTATION IMMUNOLOGY
Yves Laure Pimentel · 30問 · 2年前11. TRANSPLANTATION IMMUNOLOGY
11. TRANSPLANTATION IMMUNOLOGY
30問 • 2年前2. LYMPHOID ORGANS
2. LYMPHOID ORGANS
Yves Laure Pimentel · 38問 · 2年前2. LYMPHOID ORGANS
2. LYMPHOID ORGANS
38問 • 2年前3. CLUSTER OF DIFFERENTIATION
3. CLUSTER OF DIFFERENTIATION
Yves Laure Pimentel · 48問 · 2年前3. CLUSTER OF DIFFERENTIATION
3. CLUSTER OF DIFFERENTIATION
48問 • 2年前4. T-CELL DIFFERENTIATION
4. T-CELL DIFFERENTIATION
Yves Laure Pimentel · 35問 · 2年前4. T-CELL DIFFERENTIATION
4. T-CELL DIFFERENTIATION
35問 • 2年前5. T CELL IMMUNODEFICIENCIES
5. T CELL IMMUNODEFICIENCIES
Yves Laure Pimentel · 18問 · 2年前5. T CELL IMMUNODEFICIENCIES
5. T CELL IMMUNODEFICIENCIES
18問 • 2年前6. STAGES IN B-CELL DIFFERENTIATION PROPIMAP
6. STAGES IN B-CELL DIFFERENTIATION PROPIMAP
Yves Laure Pimentel · 44問 · 2年前6. STAGES IN B-CELL DIFFERENTIATION PROPIMAP
6. STAGES IN B-CELL DIFFERENTIATION PROPIMAP
44問 • 2年前7. B CELL IMMUNODEFICIENCIES
7. B CELL IMMUNODEFICIENCIES
Yves Laure Pimentel · 23問 · 2年前7. B CELL IMMUNODEFICIENCIES
7. B CELL IMMUNODEFICIENCIES
23問 • 2年前8. COMBINED T CELL AND B CELL DEFICIENCIES
8. COMBINED T CELL AND B CELL DEFICIENCIES
Yves Laure Pimentel · 34問 · 2年前8. COMBINED T CELL AND B CELL DEFICIENCIES
8. COMBINED T CELL AND B CELL DEFICIENCIES
34問 • 2年前9. COMPARISON OF T AND B CELLS
9. COMPARISON OF T AND B CELLS
Yves Laure Pimentel · 12問 · 2年前9. COMPARISON OF T AND B CELLS
9. COMPARISON OF T AND B CELLS
12問 • 2年前10. LABORATORY IDENTIFICATION OF LYMPHOCYTES
10. LABORATORY IDENTIFICATION OF LYMPHOCYTES
Yves Laure Pimentel · 16問 · 2年前10. LABORATORY IDENTIFICATION OF LYMPHOCYTES
10. LABORATORY IDENTIFICATION OF LYMPHOCYTES
16問 • 2年前11. NATURAL KILLER CELLS OR THIRD POPULATION CELL
11. NATURAL KILLER CELLS OR THIRD POPULATION CELL
Yves Laure Pimentel · 15問 · 2年前11. NATURAL KILLER CELLS OR THIRD POPULATION CELL
11. NATURAL KILLER CELLS OR THIRD POPULATION CELL
15問 • 2年前12. ANTIBODY
12. ANTIBODY
Yves Laure Pimentel · 79問 · 2年前12. ANTIBODY
12. ANTIBODY
79問 • 2年前13. TYPES OF ANTIBODIES
13. TYPES OF ANTIBODIES
Yves Laure Pimentel · 97問 · 2年前13. TYPES OF ANTIBODIES
13. TYPES OF ANTIBODIES
97問 • 2年前14. MONOCLONAL ANTIBODIES
14. MONOCLONAL ANTIBODIES
Yves Laure Pimentel · 11問 · 2年前14. MONOCLONAL ANTIBODIES
14. MONOCLONAL ANTIBODIES
11問 • 2年前1. INTERLEUKINS
1. INTERLEUKINS
Yves Laure Pimentel · 23問 · 2年前1. INTERLEUKINS
1. INTERLEUKINS
23問 • 2年前2. INTERFERONS
2. INTERFERONS
Yves Laure Pimentel · 28問 · 2年前2. INTERFERONS
2. INTERFERONS
28問 • 2年前3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY
3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY
Yves Laure Pimentel · 8問 · 2年前3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY
3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY
8問 • 2年前4. COMPLEMENT SYSTEM
4. COMPLEMENT SYSTEM
Yves Laure Pimentel · 19問 · 2年前4. COMPLEMENT SYSTEM
4. COMPLEMENT SYSTEM
19問 • 2年前15. COMPLEMENT SYSTEM
15. COMPLEMENT SYSTEM
Yves Laure Pimentel · 76問 · 2年前15. COMPLEMENT SYSTEM
15. COMPLEMENT SYSTEM
76問 • 2年前16. SYSTEM CONTROLS/COMPLEMENT REGULATION
16. SYSTEM CONTROLS/COMPLEMENT REGULATION
Yves Laure Pimentel · 21問 · 2年前16. SYSTEM CONTROLS/COMPLEMENT REGULATION
16. SYSTEM CONTROLS/COMPLEMENT REGULATION
21問 • 2年前17. COMPLEMENT AND DISEASE STATES
17. COMPLEMENT AND DISEASE STATES
Yves Laure Pimentel · 29問 · 2年前17. COMPLEMENT AND DISEASE STATES
17. COMPLEMENT AND DISEASE STATES
29問 • 2年前18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)
18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)
Yves Laure Pimentel · 19問 · 2年前18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)
18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)
19問 • 2年前19. CYTOKINES
19. CYTOKINES
Yves Laure Pimentel · 22問 · 2年前19. CYTOKINES
19. CYTOKINES
22問 • 2年前20. INTERLEUKINS
20. INTERLEUKINS
Yves Laure Pimentel · 24問 · 2年前20. INTERLEUKINS
20. INTERLEUKINS
24問 • 2年前21. INTERFERONS, TNF, TGF, CHEMOKINE
21. INTERFERONS, TNF, TGF, CHEMOKINE
Yves Laure Pimentel · 21問 · 2年前21. INTERFERONS, TNF, TGF, CHEMOKINE
21. INTERFERONS, TNF, TGF, CHEMOKINE
21問 • 2年前1. SERO
1. SERO
Yves Laure Pimentel · 54問 · 2年前1. SERO
1. SERO
54問 • 2年前2. PRECIPITATION
2. PRECIPITATION
Yves Laure Pimentel · 38問 · 2年前2. PRECIPITATION
2. PRECIPITATION
38問 • 2年前3. PASSIVE IMMUNODIFFUSION
3. PASSIVE IMMUNODIFFUSION
Yves Laure Pimentel · 17問 · 2年前3. PASSIVE IMMUNODIFFUSION
3. PASSIVE IMMUNODIFFUSION
17問 • 2年前4. OUCHTERLONY
4. OUCHTERLONY
Yves Laure Pimentel · 15問 · 2年前4. OUCHTERLONY
4. OUCHTERLONY
15問 • 2年前5. ELECTROPHORETIC TECHNIQUE
5. ELECTROPHORETIC TECHNIQUE
Yves Laure Pimentel · 9問 · 2年前5. ELECTROPHORETIC TECHNIQUE
5. ELECTROPHORETIC TECHNIQUE
9問 • 2年前6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)
6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)
Yves Laure Pimentel · 11問 · 2年前6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)
6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)
11問 • 2年前7. IMMUNOFIXATION ELECTROPHORESIS
7. IMMUNOFIXATION ELECTROPHORESIS
Yves Laure Pimentel · 29問 · 2年前7. IMMUNOFIXATION ELECTROPHORESIS
7. IMMUNOFIXATION ELECTROPHORESIS
29問 • 2年前問題一覧
1
d. Four gamma chains
2
d. Metamyelocyte
3
b. Eosinophils and basophils
4
a. Degrading antigen and presenting it to lymphocytes
5
d. Plasma cell
6
a. Pelger-Huët anomaly
7
d.. May-Hegglin anomaly
8
c. Alder-Reilly anomaly
9
b. Gaucher disease
10
d. All of the above
11
c. IL-2 receptor
12
c. Döhle bodies
13
a. Solid tumors
14
b. HTLV-1
15
d. Allowing cells with damaged DNA to progress through the cell cycle
16
Which one of the following is an example of a tumor sup- pressor gene? a. ABL1 b. RARA c. TP53 d. JAK2
17
d. Targeted therapy
18
b. 20%
19
b. Lipids
20
b. Monocytic
21
d. t(15;17)(q22;q12)
22
b. AML with t(16;16)(p13;q22)
23
c. AML with t(9;11)(p22;q23)
24
c. Acute monoblastic/monocytic leukemia
25
b. Pronormoblasts and basophilic normoblasts
26
b. Acute megakaryoblastic
27
c. t(9;22)
28
d. FISH positive for BCR-ABL1 fusion
29
c. JAK2 V617F
30
c. Erythrocytosis, thrombocytosis, and granulocytosis
31
a. Teardrop-shaped erythrocytes, nucleated RBCs, immature granulocytes
32
b. ET
33
a. Dyspoiesis
34
a. Popcorn cells
35
b. GP IIb/IIIa
36
a. VWF
37
d. Phosphatidylserine
38
c. Dense tubular system
39
a. Serotonin
40
a. Serotonin
41
d. Prostacyclin
42
c. Are largely composed of platelets and VWF
43
b. Endothelial cell
44
a. Lead to the formation of a stable fibrin clot
45
c. Tissue factor
46
b. Fibrinogen
47
d. Carboxylates the factors to allow calcium binding
48
c. APC and protein S
49
d. Factor XIII
50
b. Mucosal bleeding
51
d. Bleeding into the joints (hemarthroses)
52
a. Glanzmann thrombasthenia
53
b. Abnormal platelet response to ristocetin
54
a. Thromboxane A2
55
b. Factor VII deficiency, the PT
56
c. Hypofibrinogenemia
57
a. Type1
58
b. Subtype 2B
59
b. Vitamin K and four-factor PCC
60
d. Factor XIII
61
a. rFVIIa
62
c. Factor V assay
63
a. APC resistance (factor V Leiden mutation)
64
b. DRVVT
65
b. 2.5
66
c. 16
67
d. Fetal hemoglobin
68
d. 21% to 27%
69
a. 2
70
d. Inflammation
71
d. Increasing the acute angle of the pusher slide
72
c. The buffer was too acidic
73
a. Rouleaux
74
c. 11.8 x 10^9/L
75
c. 200,000
76
b. 44,000
77
b. The platelets are adhering to WBCs.
78
b. Internal complexity of the cell
79
c. MCV will be increased and RBC count will be decreased.
80
c. MCV
81
c. Diagnosis of leukemias and lymphomas
82
b. It is expressed on all hematopoietic cells, with the exception of megakaryocytes and late erythroid precursors
83
a. CD71
84
b. CD19, CD34, and CD10
85
a. It is best defined as selection of a target population for flow cytometric analysis
86
a. Loss of certain antigens compared with the normal T cell population
87
c. CD15, CD33, and CD13
88
c. Clot-based test results are falsely prolonged
89
a. Platelet aggregometry
90
b. 10,000/uL
91
a. 0.32 mL
92
d. Glanzmann thrombasthenia
93
b. Serotonin release assay
94
b. Ristocetin
95
b. Factor VII
96
a. Vitamin K deficiency
97
b. Lupus anticoagulant
98
d. DIC
99
c. Photo-optical clot detection
100
a. It is not affected by lipemia in the test specimen